Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study

Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study

Xiaoxiao Zhao,1,&ast; Li Song,1,&ast; Jiannan Li,1 Jinying Zhou,1 Nan Li,1 Shaodi Yan,2 Runzhen Chen,1 Ying Wang,1 Chen Liu,1 Peng Zhou,1 Zhaoxue Sheng,1 Yi Chen,1 Hanjun Zhao,1 Hongbing Yan2 1Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union...

Full description

Bibliographic Details
Main Authors:	Zhao X, Song L, Li J, Zhou J, Li N, Yan S, Chen R, Wang Y, Liu C, Zhou P, Sheng Z, Chen Y, Zhao H, Yan H
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-01-01
Series:	Journal of Inflammation Research
Subjects:	triglyceride glucose index proprotein convertase subtilisin/kexin type 9 mortality type 2 diabetes st-segment elevation myocardial infarction primary percutaneous coronary intervention
Online Access:	https://www.dovepress.com/effect-of-triglyceride-glucose-indices-and-circulating-pcsk9-associate-peer-reviewed-fulltext-article-JIR

Similar Items

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01)

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study
by: Runzhen Chen, et al.
Published: (2022-10-01)

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction
by: Jun Sawaguchi, et al.
Published: (2022-12-01)

The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (<i>PCSK7</i>) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

ASSOCIATION OF POLYMORPHISM IN PCSK9 GENE WITH LIPID PR OFILE IN RUSSIAN POPULATION
by: K. S. Astrakova, et al.
Published: (2016-06-01)

Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
by: Wen Guo, et al.
Published: (2018-01-01)

PCSK9 inhibitors in clinical practice: Novel directions and new experiences
by: Loukianos S. Rallidis, et al.
Published: (2020-07-01)

PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01)

The Impact of PCSK9 Gene Polymorphisms on Ischemic Stroke: A Systematic Review and Meta-Analysis
by: Jianhong Wang, et al.
Published: (2024-03-01)

Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation
by: Nattayaporn Apaijai, et al.
Published: (2019-01-01)

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
by: V.A. Serhiyenko, et al.
Published: (2023-03-01)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
by: Bowen Lou, et al.
Published: (2022-10-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
by: Erica Gianazza, et al.
Published: (2023-06-01)

PCSK9 deficiency alters brain lipid composition without affecting brain development and function
by: Angela Pärn, et al.
Published: (2023-01-01)

Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice
by: Oliver C. McGehee, et al.
Published: (2023-02-01)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
by: Thorsten M. Leucker, et al.
Published: (2020-07-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
by: Zhenxian Li, et al.
Published: (2023-05-01)

NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study
by: Jia Peng, et al.
Published: (2022-01-01)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022-09-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
by: Khursheed Muzammil, et al.
Published: (2024-03-01)

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population
by: Yiming Wu, et al.
Published: (2022-04-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
by: Hua Cai, et al.
Published: (2023-09-01)

Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells
by: Yanqiang Zou, et al.
Published: (2022-05-01)

Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund
by: Beata Bobrowska, et al.
Published: (2022-08-01)

Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin
by: Keiji Hirai, et al.
Published: (2020-07-01)

Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
by: Alessandro Morotti, et al.
Published: (2022-09-01)

Loss of Hepatic Surf4 Depletes Lipid Droplets in the Adrenal Cortex but Does Not Impair Adrenal Hormone Production
by: Xiaole Chang, et al.
Published: (2021-11-01)

Corrigendum: Loss of hepatic Surf4 depletes lipid droplets in the adrenal cortex but does not impair adrenal hormone production
by: Xiaole Chang, et al.
Published: (2023-05-01)

Variants of <i>PCSK9</i> Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans. The GEA Project
by: Erasmo Zamarrón-Licona, et al.
Published: (2021-04-01)

Susceptibility of PCSK2 Polymorphism to Hirschsprung Disease in Southern Chinese Children
by: Wang B, et al.
Published: (2023-05-01)

Rare Heterozygous <i>PCSK1</i> Variants in Human Obesity: The Contribution of the p.Y181H Variant and a Literature Review
by: Evelien Van Dijck, et al.
Published: (2022-09-01)